<p>PureTech Health（纳斯达克代码：PRTC - 获取免费报告）于周三发布了其财报。该公司报告本季度每股收益为（$1.35），超出市场共识预期的（$1.94）$0.59，FiscalAI 报道。该公司本季度的收入为 140 万美元，而分析师预期为 190 万美元。</p>
<p>获取 <strong>PureTech Health</strong> 的提醒：</p>
<p>以下是来自 PureTech Health 电话会议的关键要点：</p>
<ul>
<li>PureTech 制定了精简的战略，计划自愿从纳斯达克退市以降低成本，提前启动创办实体以利用外部资本，并增加对股东的资本回报。</li>
<li><strong>Celea Therapeutics</strong> 的融资被描述为 “基本完成”，预计在 2026 年第三季度初完成，以支持 deupirfenidone 的 III 期 SURPASS‑IPF 试验，这是 PureTech 的一个近期价值转折点。</li>
<li><strong>Gallop</strong> 的 LYT‑200 报告了积极的 I-B 期顶线数据（12 mg/kg 剂量，良好的安全性，剂量依赖性活性），促使其优先考虑复发性难治高风险 MDS，并计划与 FDA 接洽进行潜在的注册试验，同时寻求外部资本。</li>
<li>截至 2026 年 3 月 31 日，PureTech 拥有约 <strong>2.481 亿美元</strong> 的现金及现金等价物，并预计运营资金至少可持续到 2028 年底，包括预计参与 Celea 和 Gallop 的融资。</li>
<li>创新引擎将遵循 LIFE 模型，以适度的资本推进概念阶段的项目，目标是在未来三年内开发最多两个候选药物（重点领域包括中枢神经系统和资本效率高的小分子）。</li>
</ul>
<h2>PureTech Health 股价下跌 4.9%</h2>
<p>周三中午交易时，纳斯达克：PRTC 股价下跌 0.89 美元，跌至 17.25 美元。该公司的交易量为 13,352 股，而其平均交易量为 4,447 股。该公司的 50 日简单移动平均为 16.87 美元，200 日简单移动平均为 17.25 美元。PureTech Health 的一年低点为 14.50 美元，一年高点为 19.92 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>另外，Weiss Ratings 在 4 月 21 日的研究报告中重申了对 PureTech Health 股票的 “卖出（d）” 评级。一位分析师对该股票给予了卖出评级，根据 MarketBeat 的数据，该股票目前的平均评级为 “卖出”。</p>
<p><strong>获取我们最新的 PureTech Health 股票分析</strong></p>
<h2>机构资金流入和流出</h2>
<p>一家机构投资者最近增加了在 PureTech Health 股票中的持仓。Pentwater Capital Management LP 在第三季度将其在 PureTech Health PLC 赞助的 ADR（纳斯达克：PRTC - 免费报告）中的持股提高了 50.0%，根据该公司最近向 SEC 提交的 13F 表格。该基金在本季度额外购买了 25,000 股后，持有 75,000 股该公司的股票。Pentwater Capital Management LP 在其最近向 SEC 提交的文件中持有的 PureTech Health 股票价值为 1,388,000 美元。对冲基金和其他机构投资者持有该公司 0.04% 的股票。</p>
<h2>关于 PureTech Health</h2>
<p>（获取免费报告）</p>
<p>PureTech Health（纳斯达克：PRTC）是一家临床阶段的生物治疗公司，专注于创造和开发一流的药物，涵盖免疫学、炎症、肿瘤学和神经科学。该公司通过在内部孵化项目并将选定资产推进为独立的、创造价值的实体来运营。其内部管道包括多个针对纤维化疾病、实体肿瘤和罕见遗传疾病的临床和临床前候选药物。</p>
<p>PureTech 的专有平台技术涵盖单克隆抗体、小分子和细胞治疗等多种形式。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过 PureTech Health</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 PureTech Health 吗？</h2>
<p>在你考虑 PureTech Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 PureTech Health 并不在名单上。</p>
<p>虽然 PureTech Health 目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PRTC

PRTCY

<p>PureTech Health（纳斯达克代码：PRTC）报告的季度每股收益为（$1.35），超出预期的（$1.94）$0.59。收入为 140 万美元，低于预期的 190 万美元。该公司计划从纳斯达克退市以降低成本，并旨在更早推出实体以实现资本杠杆。PureTech 拥有 2.481 亿美元的现金，确保其运营资金可持续到 2028 年。尽管股价下跌 4.9% 至 17.25 美元，分析师仍维持 “卖出” 评级，机构投资者则增加了持股。PureTech 专注于在多个治疗领域开发首创药物</p>

<p>PureTech Health (NASDAQ:PRTC - Get Free Report) issued its earnings results on Wednesday. The company reported ($1.35) earnings per share for the quarter, topping the consensus estimate of ($1.94) by $0.59, FiscalAI reports. The firm had revenue of $1.40 million during the quarter, compared to analysts' expectations of $1.90 million.</p>
<div class="lb-trans"><p>PureTech Health（纳斯达克代码：PRTC - 获取免费报告）于周三发布了其财报。该公司报告本季度每股收益为（$1.35），超出市场共识预期的（$1.94）$0.59，FiscalAI 报道。该公司本季度的收入为 140 万美元，而分析师预期为 190 万美元。</p>
</div><p>Get <strong>PureTech Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>PureTech Health</strong> 的提醒：</p>
</div><p>Here are the key takeaways from PureTech Health's conference call:</p>
<div class="lb-trans"><p>以下是来自 PureTech Health 电话会议的关键要点：</p>
</div><ul>
<li>PureTech has a refined strategy to operate a <strong>leaner hub</strong>, voluntarily delist from Nasdaq to reduce costs, launch founded entities earlier to leverage external capital, and increase capital returns to shareholders.</li>
<li><strong>Celea Therapeutics</strong> fundraising is described as &#34;substantially complete&#34; with a targeted close in early Q3 2026 to support a Phase III SURPASS‑IPF trial for deupirfenidone, a near‑term value inflection for PureTech.</li>
<li><strong>Gallop</strong>'s LYT‑200 reported positive Phase I‑B top‑line data (12 mg/kg dose, good safety, dose‑dependent activity), prompting prioritization of relapsed refractory high‑risk MDS and plans to engage the FDA for a potentially registration‑enabling trial while seeking external capital.</li>
<li>PureTech held approximately <strong>$248.1m</strong> in cash and equivalents as of March 31, 2026 and expects operational runway at least through the end of 2028, inclusive of anticipated participation in Celea and Gallop financings.</li>
<li>The innovation engine will follow the LIFE model to progress concept‑stage programs with modest capital, targeting up to two development candidates over the next three years (focus areas include CNS and capital‑efficient small molecules).</li>
</ul>
<div class="lb-trans"><ul>
<li>PureTech 制定了精简的战略，计划自愿从纳斯达克退市以降低成本，提前启动创办实体以利用外部资本，并增加对股东的资本回报。</li>
<li><strong>Celea Therapeutics</strong> 的融资被描述为 “基本完成”，预计在 2026 年第三季度初完成，以支持 deupirfenidone 的 III 期 SURPASS‑IPF 试验，这是 PureTech 的一个近期价值转折点。</li>
<li><strong>Gallop</strong> 的 LYT‑200 报告了积极的 I-B 期顶线数据（12 mg/kg 剂量，良好的安全性，剂量依赖性活性），促使其优先考虑复发性难治高风险 MDS，并计划与 FDA 接洽进行潜在的注册试验，同时寻求外部资本。</li>
<li>截至 2026 年 3 月 31 日，PureTech 拥有约 <strong>2.481 亿美元</strong> 的现金及现金等价物，并预计运营资金至少可持续到 2028 年底，包括预计参与 Celea 和 Gallop 的融资。</li>
<li>创新引擎将遵循 LIFE 模型，以适度的资本推进概念阶段的项目，目标是在未来三年内开发最多两个候选药物（重点领域包括中枢神经系统和资本效率高的小分子）。</li>
</ul>
</div><h2>PureTech Health Trading Down 4.9%</h2>
<div class="lb-trans"><h2>PureTech Health 股价下跌 4.9%</h2>
</div><p>NASDAQ:PRTC traded down $0.89 during mid-day trading on Wednesday, hitting $17.25. The company had a trading volume of 13,352 shares, compared to its average volume of 4,447. The business has a fifty day simple moving average of $16.87 and a 200-day simple moving average of $17.25. PureTech Health has a 1 year low of $14.50 and a 1 year high of $19.92.</p>
<div class="lb-trans"><p>周三中午交易时，纳斯达克：PRTC 股价下跌 0.89 美元，跌至 17.25 美元。该公司的交易量为 13,352 股，而其平均交易量为 4,447 股。该公司的 50 日简单移动平均为 16.87 美元，200 日简单移动平均为 17.25 美元。PureTech Health 的一年低点为 14.50 美元，一年高点为 19.92 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Separately, Weiss Ratings reaffirmed a &#34;sell (d)&#34; rating on shares of PureTech Health in a research report on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 4 月 21 日的研究报告中重申了对 PureTech Health 股票的 “卖出（d）” 评级。一位分析师对该股票给予了卖出评级，根据 MarketBeat 的数据，该股票目前的平均评级为 “卖出”。</p>
</div><p><strong>Get Our Latest Stock Analysis on PureTech Health</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 PureTech Health 股票分析</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>An institutional investor recently raised its position in PureTech Health stock. Pentwater Capital Management LP lifted its holdings in shares of PureTech Health PLC Sponsored ADR (NASDAQ:PRTC - Free Report) by 50.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 75,000 shares of the company's stock after acquiring an additional 25,000 shares during the quarter. Pentwater Capital Management LP owned 0.31% of PureTech Health worth $1,388,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 0.04% of the company's stock.</p>
<div class="lb-trans"><p>一家机构投资者最近增加了在 PureTech Health 股票中的持仓。Pentwater Capital Management LP 在第三季度将其在 PureTech Health PLC 赞助的 ADR（纳斯达克：PRTC - 免费报告）中的持股提高了 50.0%，根据该公司最近向 SEC 提交的 13F 表格。该基金在本季度额外购买了 25,000 股后，持有 75,000 股该公司的股票。Pentwater Capital Management LP 在其最近向 SEC 提交的文件中持有的 PureTech Health 股票价值为 1,388,000 美元。对冲基金和其他机构投资者持有该公司 0.04% 的股票。</p>
</div><h2>About PureTech Health</h2>
<div class="lb-trans"><h2>关于 PureTech Health</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>PureTech Health NASDAQ: PRTC is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.</p>
<div class="lb-trans"><p>PureTech Health（纳斯达克：PRTC）是一家临床阶段的生物治疗公司，专注于创造和开发一流的药物，涵盖免疫学、炎症、肿瘤学和神经科学。该公司通过在内部孵化项目并将选定资产推进为独立的、创造价值的实体来运营。其内部管道包括多个针对纤维化疾病、实体肿瘤和罕见遗传疾病的临床和临床前候选药物。</p>
</div><p>PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.</p>
<div class="lb-trans"><p>PureTech 的专有平台技术涵盖单克隆抗体、小分子和细胞治疗等多种形式。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than PureTech Health</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 PureTech Health</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in PureTech Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 PureTech Health 吗？</h2>
</div><p>Before you consider PureTech Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 PureTech Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 PureTech Health 并不在名单上。</p>
</div><p>While PureTech Health currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 PureTech Health 目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

PureTech Health (NASDAQ:PRTC) Posts Quarterly Earnings Results, Beats Estimates By $0.59 EPS

PureTech Health（NASDAQ:PRTC）公布季度财报，每股收益比预期高出 0.59 美元